MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology, efficacy and safety.
This review presents the pharmacology, clinical efficacy and safety of MP29-02 (Dymista®), a unique product for the treatment of allergic rhinitis. Allergic rhinitis is often thought of more as a nuisance than a meaningful medical condition, and the health impact of allergic rhinitis can easily be underestimated. As a result, allergic rhinitis can be undertreated, expectations for relief may not be met, and patients may be left dissatisfied and non-compliant with their medications. MP29-02 is the only currently available allergic rhinitis medication to provide potent early-phase histamine-receptor blocking and long-term anti-inflammatory effects in a single intranasal formulation and delivery system that represents an advance in the therapy of allergic rhinitis, in particular for patients with moderate-to-severe disease.
Allergy and Asthma Associates of Southern California, Mission Viejo, CA, USA.
William E
WE
Berger
D000281:Administration, Intranasal; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D016503:Drug Delivery Systems; D006633:Histamine Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D017060:Patient Satisfaction; D010793:Phthalazines / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D011968:Receptors, Histamine / Q000378:metabolism; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D000730:Androstadienes; D004338:Drug Combinations; D006633:Histamine Antagonists; C573864:MP29-02; D010793:Phthalazines; D011968:Receptors, Histamine